Resolve Therapeutics Secures Path to Liquidity via Option Deal with Takeda
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 3 (Table of Contents)
Published: 14 Mar-2013
DOI: 10.3833/pdr.v2013.i3.1910 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Takeda Pharmaceutical has partnered with Resolve Therapeutics, a spin-out from the University of Washington, to develop novel compounds for the treatment of systemic lupus erythematosus and other autoimmune diseases, including the company’s lead programme RSLV-132...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS